



Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases.

Primary IR Contact

Investor Relations

Phone: 617.679.5500

E-mail:

ir@iderapharma.com

Stock Information

IDRA (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$1.76
Change (%)	▼ 0.14 (7.37%)
Volume	1,164,968
52 Week Low	\$1.30
Market Cap	\$283,381,930
Rolling EPS	-0.31
PE Ratio	0
Shares Outstanding	149,148,384



Data as of 06/27/17 4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Headlines

Jun 22, 2017

Idera Announces FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma

Events

There are currently no events scheduled.

Jun 05, 2017

Idera to Present at the Jefferies 2017 Healthcare
Conference

May 04, 2017

Idera Pharmaceuticals Reports First Quarter 2017 Financial
Results and Provides Corporate Update

SEC Filings

Filing Date	Form
06/09/17	4
06/09/17	4
06/09/17	4
06/09/17	4

Corporate Governance

Sudhir Agrawal, D.Phil.	President of Research
Louis J. Arcudi III, MBA	Senior Vice President of Operations, Chief Financial Officer, Treasurer, and Secretary
Mark J. Casey	Senior Vice President, General Counsel and Secretary of the Board of Directors
Jill Conwell	Vice President, Human Resources
Robert Doody Jr.	Vice President, Investor Relations and Corporate Communications
Clayton Fletcher	Senior Vice President, Business Development and Strategic Planning
Joanna Horobin, M.B., Ch.B.	Senior Vice President, Chief Medical Officer
Vincent Milano	Chief Executive Officer